Search

Skip to main content Accessibility help

Home
Search

Only show content I have access to (0)

Chapters (1)

Last 3 years (1)

From year:

To year:

Apply

Medicine (1)

secondary cytoreductive surgery

Cambridge University Press (1)

View selected items
Save to my bookmarks
Export citations
Download PDF (zip)
Save to Kindle
Save to Dropbox
Save to Google Drive
Save content to
To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to .

To save content items to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Please be advised that item(s) you selected are not available.
You are about to save
Your Kindle email address

Please provide your Kindle email.

@free.kindle.com @kindle.com (service fees apply)

By using this service, you agree that you will only keep content for personal use, and will not openly distribute them via Dropbox, Google Drive or other file sharing services

1 results

Debate 20A - Should Patients with Platinum-sensitive Recurrent Ovarian Cancer Undergo Secondary Cytoreduction prior to Receiving Platinum-containing Second-line Chemotherapy?
from Section III - Ovarian Cancer
- By Sarah Ehmann, Andreas du Bois, Mareike Bommert
Edited by Dennis S. Chi, Memorial Sloan-Kettering Cancer Center, New York, Nisha Lakhi, Richmond University Medical Center, Staten Island, Nicoletta Colombo, University of Milan-Bicocca
Book:

50 Big Debates in Gynecologic Oncology

Published online:

20 July 2023

Print publication:

03 August 2023, pp 113-115
- Chapter
- - Get access
    
    Check if you have access via personal or institutional login
    
    Log in Register
- Export citation
Summary

The treatment of recurrent ovarian cancer and the role of secondary cytoreductive surgery has been discussed for many years. Three phase III trials focused on that aspect with different results, including patients with the first relapse and a platinum-free interval of at least six months. The GOG 213 trial failed to show an OS benefit for patients with secondary cytoreduction. The interim analysis of the SOC1 trial showed a PFS benefit of 5.5 months (17.4 versus 11.9) favoring surgery, OS data are not mature yet. The DESKTOP III trial revealed an extraordinary OS benefit of 14.5 months for patients with complete resection compared to patients without surgery (60.7 vs. 46.2 months). Therefore, secondary cytoreductive surgery should be offered to suitable patients. The selection of the right patient (e.g. by AGO score) and the right center is the most important step to take to achieve the best results for our patients.

Search Results

Refine search

Refine search

Actions for selected content:

1 results

Debate 20A - Should Patients with Platinum-sensitive Recurrent Ovarian Cancer Undergo Secondary Cytoreduction prior to Receiving Platinum-containing Second-line Chemotherapy?

Summary

Search Results

Refine search

Refine search

Actions for selected content:

Save Search

1 results

Debate 20A - Should Patients with Platinum-sensitive Recurrent Ovarian Cancer Undergo Secondary Cytoreduction prior to Receiving Platinum-containing Second-line Chemotherapy?

Summary